[{"id":"fc09571b-5ebb-4487-ae57-9f6522ab1488","acronym":"","url":"https://clinicaltrials.gov/study/NCT04487236","created_at":"2021-01-18T21:32:26.670Z","updated_at":"2024-07-02T16:35:41.443Z","phase":"Phase 1","brief_title":"Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors","source_id_and_acronym":"NCT04487236","lead_sponsor":"Suzhou Zanrong Pharma Limited","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • capecitabine • perzebertinib (RG6596)"],"overall_status":"Recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 10/15/2020","start_date":" 10/15/2020","primary_txt":" Primary completion: 12/30/2023","primary_completion_date":" 12/30/2023","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2023-08-01"}]